TNFSF11 and arthritic joint disease: Moreover, similar experiments performed by La Branche et al., using an adjuvant-induced arthritis model showed that tocacitinib decreases edema, inflammation and suppress osteoclast-mediated structural damage to arthritic joints, being this secondary to a decrease in RANKL production [201].